Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


JCR To Be First To Produce Local Biotech Generic In Japan

This article was originally published in PharmAsia News

Executive Summary

Japan's JCR Pharmaceuticals plans to make its entry into the mass-produced biotech generic sector in Japan with an erythropoietin protein-based treatment for anemia due to reduced kidney function. JCR said it expects to get government clearance for its generic at the beginning of next year and then produce it in a special factory it plans to construct by next summer. The JCR drug would be only the second bioengineered generic to be approved for sale in the country, the first being a human growth hormone that Sandoz imports from Australia. JCR plans to co-market the drug with Kissei Pharmaceutical. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts